The Health Care M&A Monthly: Pharma Deals Target Consumer Health And Generic Drug Markets
Email Editor Last month’s gossip has become this month’s headline news. Two rumors in the pharma industry, which were noted in last month’s issue, have now materialized as full-fledged deals. Both reflect the ongoing attractiveness of consumer products and generic...The Health Care M&A Monthly: $12.8 Billion Deal Unites Thermo Electron and Fisher Scientific
Email Editor Mega-deals, among their many attractions, are interesting because of the way they may change the landscape of an industry. By all rights, Thermo Electron Corporation’s (NYSE: TMO) proposed $12.8 billion acquisition of Fisher Scientific International, Inc....The Health Care M&A Monthly: Medical Device Merger Mania
Email Editor The month of April saw a surge of dealmaking in the Medical Device sector, with a total of 14 transactions announced. Based on revealed prices, the total amount spent to fund this activity was $4.7 billion, or 59% of all M&A dollars spent during the...The Health Care M&A Monthly: March Merger Mania in Pharma
Europe Sees A Flurry of Springtime Dealmaking In The Pharmaceutical Industry, As Bayer Leads The Pack With A $19.5 Billion Bid for Schering AG March saw a surge of M&A activity in the pharmaceutical sector, particularly in Europe. A total of 17 deals were...The Health Care M&A Monthly: To The Winners Go The Spoils… Boston Scientific’s $27 Billion Bid for Guidant Trumps Johnson & Johnson’s While Abbott Laboratories Lands Itself a Strong Vascular Business
Email Editor Knowing when to hold ‘em and knowing when to fold ‘em are useful skills in more games than just poker. The bidding war for Guidant Corporation (NYSE: GDT), raging over the past two months, has finally come to an end with Guidant’s board accepting Boston...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
